Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966695 | 1.00 | FEN1 (0.40) | FEN1SMN1; SMN2KDM4EMAPK1HTT | |
| SCHEMBL1967836 | 0.91 | P2RX3 (0.39) | KDM4EHTTHIF1AMEN1KMT2A | |
| SCHEMBL1967838 | 0.91 | P2RX3 (0.39) | KDM4EHTTHIF1AMEN1KMT2A | |
| SCHEMBL1969468 | 0.89 | ITGB1 (0.41) | FEN1SMN1; SMN2KDM4EMAPK1HTT | |
| SCHEMBL1969464 | 0.89 | ITGB1 (0.41) | FEN1SMN1; SMN2KDM4EMAPK1HTT | |
| SCHEMBL1967178 | 0.89 | CNR2 (0.42) | SMN1; SMN2KDM4EMAPK1HTTHIF1A | |
| SCHEMBL1967179 | 0.89 | CNR2 (0.42) | SMN1; SMN2KDM4EMAPK1HTTHIF1A | |
| SCHEMBL1968476 | 0.88 | EGLN1 (0.42) | KDM4EHTTITGB1ITGA4ITGB7 | |
| SCHEMBL1968474 | 0.88 | EGLN1 (0.42) | KDM4EHTTITGB1ITGA4ITGB7 | |
| SCHEMBL1971151 | 0.88 | EGLN1 (0.42) | KDM4EHTTITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | claimed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | claimed |
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | FEN1 1106/4885SMN1; SMN2 3833/4885KDM4E 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.